Skip to main content
Journal cover image

NGM282, A Novel Variant of FGF-19, Demonstrates Biologic Activity in Primary Biliary Cirrhosis Patients with an Incomplete Response to Ursodeoxycholic Acid: Results of a Phase 2 Multicenter, Randomized, Double Blinded, Placebo Controlled Trial

Publication ,  Conference
Mayo, MJ; Wigg, AJ; Roberts, SK; Arnold, H; Hassanein, TI; Leggett, BA; Bate, JP; Weltman, M; Carey, EJ; Muir, AJ; McCaughan, G; Bollipo, SJ ...
Published in: HEPATOLOGY
October 1, 2015

Duke Scholars

Published In

HEPATOLOGY

EISSN

1527-3350

ISSN

0270-9139

Publication Date

October 1, 2015

Volume

62

Start / End Page

263A / 264A

Location

San Francisco, CA

Publisher

WILEY-BLACKWELL

Conference Name

66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD)

Related Subject Headings

  • Gastroenterology & Hepatology
  • 3204 Immunology
  • 3202 Clinical sciences
  • 1107 Immunology
  • 1103 Clinical Sciences
  • 1101 Medical Biochemistry and Metabolomics
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Mayo, M. J., Wigg, A. J., Roberts, S. K., Arnold, H., Hassanein, T. I., Leggett, B. A., … Thompson, A. J. (2015). NGM282, A Novel Variant of FGF-19, Demonstrates Biologic Activity in Primary Biliary Cirrhosis Patients with an Incomplete Response to Ursodeoxycholic Acid: Results of a Phase 2 Multicenter, Randomized, Double Blinded, Placebo Controlled Trial. In HEPATOLOGY (Vol. 62, pp. 263A-264A). San Francisco, CA: WILEY-BLACKWELL.
Mayo, Marlyn J., Alan J. Wigg, Stuart K. Roberts, Hays Arnold, Tarek I. Hassanein, Barbara A. Leggett, John P. Bate, et al. “NGM282, A Novel Variant of FGF-19, Demonstrates Biologic Activity in Primary Biliary Cirrhosis Patients with an Incomplete Response to Ursodeoxycholic Acid: Results of a Phase 2 Multicenter, Randomized, Double Blinded, Placebo Controlled Trial.” In HEPATOLOGY, 62:263A-264A. WILEY-BLACKWELL, 2015.
Mayo MJ, Wigg AJ, Roberts SK, Arnold H, Hassanein TI, Leggett BA, Bate JP, Weltman M, Carey EJ, Muir AJ, McCaughan G, Bollipo SJ, Gordon SC, Angus PW, Riordan S, Shiffman ML, Young E, Ling L, Luo J, Elliott M, Rossi S, DePaoli AM, Thompson AJ. NGM282, A Novel Variant of FGF-19, Demonstrates Biologic Activity in Primary Biliary Cirrhosis Patients with an Incomplete Response to Ursodeoxycholic Acid: Results of a Phase 2 Multicenter, Randomized, Double Blinded, Placebo Controlled Trial. HEPATOLOGY. WILEY-BLACKWELL; 2015. p. 263A-264A.
Journal cover image

Published In

HEPATOLOGY

EISSN

1527-3350

ISSN

0270-9139

Publication Date

October 1, 2015

Volume

62

Start / End Page

263A / 264A

Location

San Francisco, CA

Publisher

WILEY-BLACKWELL

Conference Name

66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD)

Related Subject Headings

  • Gastroenterology & Hepatology
  • 3204 Immunology
  • 3202 Clinical sciences
  • 1107 Immunology
  • 1103 Clinical Sciences
  • 1101 Medical Biochemistry and Metabolomics